American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping…
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Natures Signal Transduction and Targeted Therapy
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE,…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Cirrus Therapeutics Raises $11 M Seed Financing to Advance Novel Ocular Gene Therapy to Reverse Underlying Age-Related Cause of Dry AMD
October 02, 2025 10:00 ET | Source: Cirrus Therapeutics, Inc. Cirrus’ lead…
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Executive summary first biocompatible pharmaceutical formulations progress to preclinical modelsnew sustained-release drug…
Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™…
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk…
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias
AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac…
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08,…
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
July 04, 2025 03:00 ET | Source: Nxera Pharma Tokyo, Japan and…
